eFFECTOR Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.1
- Today's High:
- $0.1198
- Open Price:
- $0.1119
- 52W Low:
- $0.0358
- 52W High:
- $0.31
- Prev. Close:
- $0.11
- Volume:
- 21397
Company Statistics
- Market Cap.:
- $0
- Book Value:
- -9.522
- Revenue TTM:
- $1.31 million
- Operating Margin TTM:
- -1809.48%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
eFFECTOR Therapeutics Inc had its IPO on 2021-03-01 under the ticker symbol EFTRW.
The company operates in the Healthcare sector and Biotechnology industry. eFFECTOR Therapeutics Inc has a staff strength of 0 employees.
Stock update
Shares of eFFECTOR Therapeutics Inc opened at $0.11 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.1 - $0.12, and closed at $0.1.
This is a -9.09% slip from the previous day's closing price.
A total volume of 21,397 shares were traded at the close of the day’s session.
In the last one week, shares of eFFECTOR Therapeutics Inc have slipped by -44.44%.
eFFECTOR Therapeutics Inc's Key Ratios
eFFECTOR Therapeutics Inc has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months eFFECTOR Therapeutics Inc’s revenue was $1.31 million with a gross profit of $0 and an EBITDA of $-23582000. The EBITDA ratio measures eFFECTOR Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, eFFECTOR Therapeutics Inc’s operating margin was -1809.48% while its return on assets stood at 0% with a return of equity of 0%.
In Q1, eFFECTOR Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 95.4%.
eFFECTOR Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.905 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into eFFECTOR Therapeutics Inc’s profitability.
eFFECTOR Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
eFFECTOR Therapeutics Inc stock pays annual dividends of $ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $21.93 million
- Total Liabilities
- $26.65 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $13000
- Dividend Payout Ratio
- 0%
eFFECTOR Therapeutics Inc ended 2024 with $21.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $21.93 million while shareholder equity stood at $-4813000.00.
eFFECTOR Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $26.65 million in other current liabilities, 4000.00 in common stock, $-153580000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.31 million and cash and short-term investments were $19.01 million. The company’s total short-term debt was $20,303,000 while long-term debt stood at $0.
eFFECTOR Therapeutics Inc’s total current assets stands at $20.89 million while long-term investments were $0 and short-term investments were $8.70 million. Its net receivables were $0 compared to accounts payable of $3.79 million and inventory worth $0.
In 2024, eFFECTOR Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $13000.
Comparatively, eFFECTOR Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.1
- 52-Week High
- $0.31
- 52-Week Low
- $0.0358
- Analyst Target Price
- $
eFFECTOR Therapeutics Inc stock is currently trading at $0.1 per share. It touched a 52-week high of $0.31 and a 52-week low of $0.31. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.16 and 200-day moving average was $0.16 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About eFFECTOR Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California.